Video

Jennifer Lane-Riefler on Financial Assistance Available for Patients with Ovarian Cancer

Author(s):

Jennifer Lane-Riefler, MCHES, CFm
Conference|Ovarian Cancer National Conference

Jennifer Lane-Riefler, MCHES, CFm, Executive Director of Cancer Services of Grant County, discusses the financial assistance opportunities available for patients with ovarian cancer.

Jennifer Lane-Riefler, MCHES, CFm, Executive Director of Cancer Services of Grant County, discusses the financial assistance opportunities available for patients with ovarian cancer. Most importantly, says Lane-Riefler, is that no patient with ovarian cancer bypass treatment completely because of financial restraints -- there is alwas financial support to be found.

Related Videos
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Image of man with grey hair.
Image of bald man in suit.
Image of woman with dark hair, smiling.
Image of woman with brown hair.
Image of man with grey hair.
Image of woman with black hair.
Image of woman with blonde hair.
Related Content
Illustration of female reproductive system.
January 13th 2025

HIPEC May Not Improve Outcomes for Recurrent Epithelial Ovarian Cancer

Spencer Feldman
Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
The FDA has accepted an NDA for avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer.
January 2nd 2025

FDA Accepts NDA for Avutometinib Plus Defactinib in KRAS+ Low-Grade Serous Ovarian Cancer

Ryan Scott
An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of woman with blondish hair.
December 30th 2024

Empowering Patients With Cancer Through Clear Clinical Trial Communication

Darlene Dobkowski, MA
A clinical trial manager emphasizes the importance of a phased approach to educating patients about complex protocols and potential side effects.
Julie S. Brokaw
December 26th 2024

Reflecting on 2024 Following an Ovarian Cancer Diagnosis

Julie S. Brokaw
Nearly 12 years after being diagnosed with ovarian cancer, Julie Brokaw believes life is a miracle.